Casma Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Casma Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on cellular degradation biology. It seeks to develop therapies that engage lysosomal and autophagy pathways to selectively degrade disease targets and slow or reverse disease progression across neurodegeneration, cancer, inflammation, and metabolic disorders. The company’s lead program centers on a TRPML1 agonist intended to restore lysosomal function in Gaucher's disease patients with Parkinson's disease, with plans to broaden to other forms of Parkinson's disease. Its PHLYTTM degrader platform aims to enable selective autophagy-based degradation of larger, more complex targets such as organelles and protein aggregates. In 2025, Casma indicated that CSM-101 is being developed as a potential disease-modifying oral therapy for Parkinson's disease and Gaucher disease, and the company has engaged with industry events to discuss its science.

Sign up for free to view info

Company overview Employee directory